289 related articles for article (PubMed ID: 28751443)
1. FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious
Balasubramaniam S; Beaver JA; Horton S; Fernandes LL; Tang S; Horne HN; Liu J; Liu C; Schrieber SJ; Yu J; Song P; Pierce W; Robertson KJ; Palmby TR; Chiu HJ; Lee EY; Philip R; Schuck R; Charlab R; Banerjee A; Chen XH; Wang X; Goldberg KB; Sridhara R; Kim G; Pazdur R
Clin Cancer Res; 2017 Dec; 23(23):7165-7170. PubMed ID: 28751443
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed,
Kristeleit RS; Oaknin A; Ray-Coquard I; Leary A; Balmaña J; Drew Y; Oza AM; Shapira-Frommer R; Domchek SM; Cameron T; Maloney L; Goble S; Lorusso D; Ledermann JA; McNeish IA
Int J Gynecol Cancer; 2019 Nov; 29(9):1396-1404. PubMed ID: 31685558
[TBL] [Abstract][Full Text] [Related]
3. FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.
Kim G; Ison G; McKee AE; Zhang H; Tang S; Gwise T; Sridhara R; Lee E; Tzou A; Philip R; Chiu HJ; Ricks TK; Palmby T; Russell AM; Ladouceur G; Pfuma E; Li H; Zhao L; Liu Q; Venugopal R; Ibrahim A; Pazdur R
Clin Cancer Res; 2015 Oct; 21(19):4257-61. PubMed ID: 26187614
[TBL] [Abstract][Full Text] [Related]
4. Rucaparib Approved for Ovarian Cancer.
Cancer Discov; 2017 Feb; 7(2):120-121. PubMed ID: 28057616
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Oza AM; Tinker AV; Oaknin A; Shapira-Frommer R; McNeish IA; Swisher EM; Ray-Coquard I; Bell-McGuinn K; Coleman RL; O'Malley DM; Leary A; Chen LM; Provencher D; Ma L; Brenton JD; Konecny GE; Castro CM; Giordano H; Maloney L; Goble S; Lin KK; Sun J; Raponi M; Rolfe L; Kristeleit RS
Gynecol Oncol; 2017 Nov; 147(2):267-275. PubMed ID: 28882436
[TBL] [Abstract][Full Text] [Related]
6. Rucaparib: First Global Approval.
Syed YY
Drugs; 2017 Apr; 77(5):585-592. PubMed ID: 28247266
[TBL] [Abstract][Full Text] [Related]
7. Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
Musella A; Bardhi E; Marchetti C; Vertechy L; Santangelo G; Sassu C; Tomao F; Rech F; D'Amelio R; Monti M; Palaia I; Muzii L; Benedetti Panici P
Cancer Treat Rev; 2018 May; 66():7-14. PubMed ID: 29605737
[TBL] [Abstract][Full Text] [Related]
8. FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer.
Anscher MS; Chang E; Gao X; Gong Y; Weinstock C; Bloomquist E; Adeniyi O; Charlab R; Zimmerman S; Serlemitsos-Day M; Ning YM; Mayrosh R; Fuller B; Trentacosti AM; Gallagher P; Bijwaard K; Philip R; Ghosh S; Fahnbulleh F; Diggs F; Arora S; Goldberg KB; Tang S; Amiri-Kordestani L; Pazdur R; Ibrahim A; Beaver JA
Oncologist; 2021 Feb; 26(2):139-146. PubMed ID: 33145877
[TBL] [Abstract][Full Text] [Related]
9. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.
Dal Molin GZ; Westin SN; Coleman RL
Future Oncol; 2018 Dec; 14(30):3101-3110. PubMed ID: 30105925
[TBL] [Abstract][Full Text] [Related]
10. Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer.
Moore DC; Ringley JT; Patel J
J Pharm Pract; 2019 Apr; 32(2):219-224. PubMed ID: 29166829
[TBL] [Abstract][Full Text] [Related]
11. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
12. Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer.
Dockery LE; Gunderson CC; Moore KN
Onco Targets Ther; 2017; 10():3029-3037. PubMed ID: 28790837
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Drew Y; Ledermann J; Hall G; Rea D; Glasspool R; Highley M; Jayson G; Sludden J; Murray J; Jamieson D; Halford S; Acton G; Backholer Z; Mangano R; Boddy A; Curtin N; Plummer R
Br J Cancer; 2016 Mar; 114(7):723-30. PubMed ID: 27002934
[TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R
Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751
[TBL] [Abstract][Full Text] [Related]
15. A profile on the FoundationFocus CDxBRCA tests.
Ford L; Wolford JE; Brown SM; Randall LM
Expert Rev Mol Diagn; 2020 Mar; 20(3):285-292. PubMed ID: 32028808
[No Abstract] [Full Text] [Related]
16. Rucaparib: a novel PARP inhibitor for
Colombo I; Lheureux S; Oza AM
Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
[TBL] [Abstract][Full Text] [Related]
17. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline
Kristeleit R; Shapiro GI; Burris HA; Oza AM; LoRusso P; Patel MR; Domchek SM; Balmaña J; Drew Y; Chen LM; Safra T; Montes A; Giordano H; Maloney L; Goble S; Isaacson J; Xiao J; Borrow J; Rolfe L; Shapira-Frommer R
Clin Cancer Res; 2017 Aug; 23(15):4095-4106. PubMed ID: 28264872
[No Abstract] [Full Text] [Related]
18. Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10.
Drew Y; Kristeleit RS; Oaknin A; Ray-Coquard I; Haris NM; Swisher EM
Oncologist; 2020 Jan; 25(1):e109-e119. PubMed ID: 31575788
[TBL] [Abstract][Full Text] [Related]
19. PARP Inhibitors for Cancer Therapy.
Lin KY; Kraus WL
Cell; 2017 Apr; 169(2):183. PubMed ID: 28388401
[TBL] [Abstract][Full Text] [Related]
20. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Swisher EM; Kristeleit RS; Oza AM; Tinker AV; Ray-Coquard I; Oaknin A; Coleman RL; Burris HA; Aghajanian C; O'Malley DM; Leary A; Welch S; Provencher D; Shapiro GI; Chen LM; Shapira-Frommer R; Kaufmann SH; Goble S; Maloney L; Kwan T; Lin KK; McNeish IA
Gynecol Oncol; 2021 Dec; 163(3):490-497. PubMed ID: 34602290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]